Phase 1/2 study of fractionated dose lutetium‐177–labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 ( <sup>177</sup> Lu‐J591) for metastatic castration‐resistant prostate cancer - Concepedia

Concepedia

Publication | Open Access

Phase 1/2 study of fractionated dose lutetium‐177–labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 ( <sup>177</sup> Lu‐J591) for metastatic castration‐resistant prostate cancer

DOI Full Paper Access

131

Citations

27

References

2019

Year

Scott T. Tagawa, Shankar Vallabhajosula, Paul J. Christos, Yuliya Jhanwar, Jaspreet S. Batra, Linda Lam, Joseph R. Osborne, Himisha Beltran, Ana M. Molina, Stanley J. Goldsmith,

Abstract

Fractionated administration of <sup>177</sup> Lu-J591 allowed higher cumulative radiation dosing. The frequency and depth of PSA decrease, overall survival, and toxicity (dose-limiting myelosuppression) increased with higher doses.

References

	Year	Citations

Page 1